Multiple Sclerosis Market Size, Share, Trends & Forecast, 2026-2034
REPORT DETAILS
Multiple Sclerosis Market Size & Forecast, 2025-2034
The global multiple sclerosis market was valued at USD 27.59 billion in 2025. The market is expected to grow at a CAGR of 5.30% from 2026 to 2034. Growth is driven by increased healthcare expenditure and ongoing developments in disease-modifying therapies.
Market Statistics
Multiple Sclerosis Market Key Takeaways: Size, Drug Classes, Routes & Regions
- North America led the global multiple sclerosis market with a 45.6% share in 2025. This is owing to the high prevalence of multiple sclerosis, an increase in drug approvals, advanced healthcare infrastructure, favorable reimbursement policies, and the presence of leading biopharmaceutical companies in the region.
- Asia Pacific is projected to grow at the fastest CAGR of 8.9% during 2026–2034. The growth is attributed to increased government initiatives, improving access to neurological care, expanding healthcare infrastructure, rising awareness of early diagnosis, and greater availability of disease-modifying therapies.
- The immunomodulators segment held the largest share of 66.8% in 2025. This is due to their ability to treat relapsing and recurrent forms of multiple sclerosis by reducing relapse frequency, slowing disease progression, and improving long-term patient outcomes.
- The immunosuppressants segment is expected to grow at the fastest CAGR of 9.4% during 2026–2034. The increased use of advanced immunosuppressive medications, expanding biologic therapies, and growing adoption for highly active or treatment-resistant multiple sclerosis are driving segment growth.
- The oral agents segment is anticipated to experience the fastest growth at a CAGR of 9.1% during 2026–2034. Their ease of administration, improved patient compliance, gradual and consistent systemic drug distribution, and reduced dependence on injectable therapies contribute significantly to the segment's growth.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Multiple Sclerosis (MS)? Disease Types, Symptoms & Treatment Landscape
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated condition that affects nerve cells in the spinal cord and brain, causing demyelination, axonal transection, and neurodegeneration. Injection, oral, and infused medications, as well as muscle relaxants, antidepressants, and physical therapy, are commonly used treatments.
Several factors are propelling the growth of the market, including increasing global awareness of the disease. Numerous organizations worldwide are actively involved in promoting awareness about this diesease in both developed and developing countries.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
For instance, the American National Multiple Sclerosis Society is a group of people affected by this disease who are dedicated to educating the public about the condition and providing support to those who are dealing with it.
Multiple sclerosis is a disease distinguished by immune-mediated effects on the central nervous system. It involves demyelination, inflammation, and degenerative processes that result in increased brain and spinal cord atrophy as well as neuroaxonal loss. Monoclonal antibodies were extensively utilized as a treatment for this disease. Ongoing clinical trials are actively investigating the potential of these antibodies to develop novel medications for the treatment of MS.
The research study provides a comprehensive analysis of the industry, assessing the market on the basis of various segments and sub-segments. It sheds light on the competitive landscape and introduces the multiple sclerosis market key players from the perspective of market share, concentration ratio, etc. The study is a vital resource for understanding the growth drivers, opportunities, and challenges in the industry.
The symptoms can vary considerably depending on the extent of neural injury and the number of affected neurons. Stiffness, urinary incontinence, numbness, fatigue, emotional disturbances, cognitive issues, and feelings of sadness are all common symptoms. The increased emphasis that major industry players are placing on research and development to develop new medications has fueled the growth of the multiple sclerosis market. Furthermore, an increase in collaborative research initiatives between pharmaceutical companies and academic institutions has boosted the market for multiple sclerosis treatments.
How Multiple Sclerosis Treatment Works: Diagnosis, DMT Selection, Monitoring & Rehabilitation
Diagnosis of Multiple Sclerosis: Diagnosis of multiple sclerosis encompasses examination of symptoms, study of medical history, and carrying out preliminary testing.
Determination of the Disease Type: The disease type is determined to choose an appropriate treatment for it.
MRI and Neurological Testing: An MRI and neurological examination are carried out in order to find out about the condition of nerves and monitor the disease process.
Choice of Treatment: Medical experts determine the most efficient treatment taking into account the type of multiple sclerosis, its severity, and the overall health state of a patient.
Monitoring of the Disease: Regular checkups and MRIs help to monitor the disease process and its treatment efficiency.
Decrease of Symptoms: Treatment will allow reducing the symptoms of the disease, such as weakness, pain, stiffness, and mobility problems.
Long-term Care: This is related to continuous treatment and rehabilitation.
Multiple Sclerosis Market Dynamics: Drivers, Opportunities, Restraints & Challenges
- The increase in the number of FDA approvals for MS disease treatment options is one of the key factors driving market growth.
- Continuous advancements in targeted monoclonal antibodies are shaping the market landscape.
- Strong developmental focus on next-gen molecules is expected to present several market opportunities.
- High treatment costs may present challenges for market development.
Growth Drivers
New DMT Approvals and Label Expansions Broaden Multiple Sclerosis Treatment Options
The increase in the number of FDA approvals will drive the growth of the market. The FDA approved several relapsing MS medications, including Kesimpta (ofatumumab), Oral Bafiertam (monomethyl fumarate), Oral Zeposia (ozanimod), and the generic form of Tecfidera. Significant advancements include the FDA's recent approval of a portable nerve stimulator designed to assist individuals experiencing walking difficulties, as well as oral Baclofen formulations aimed at alleviating muscular stiffness.
The FDA-approved multiple sclerosis treatment expands not only physicians' toolkit for tailoring treatment plans to individual patient needs but also provides newfound hope for improved outcomes and quality of life. As researchers explore further into the underlying mechanisms of MS and pharmaceutical companies continue to invest in advanced research and development, the accelerating pace of FDA approvals signals a promising era of advancements in the management and treatment.
High-Efficacy Anti-CD20 and Immune-Reconstitution Therapies Reshape MS Treatment
There have been remarkable advancements in the treatment of multiple sclerosis over the past few years that enable patients to manage the condition better than before. The use of high-efficiency disease-modifying multiple sclerosis drugs can be helpful in preventing relapses as well as the advancement of the disease. Treatment options such as infusion therapy and immune therapies can be made available for those with moderate to severe MS. Oral therapies are now available that make it easier for patients to take the medicines. In addition to this, there is research being done on developing therapies and treatments with fewer side effects.
Biomarkers and Personalized Treatment Selection Gain Importance in Multiple Sclerosis
Personalized medicine is revolutionizing treatment options for multiple sclerosis based on individual needs. There are several criteria that influence the choice of treatment strategies by medical practitioners. Research conducted through the use of biomarkers is enabling scientists to identify individuals who would benefit much from particular types of treatments. This is achieved through the use of genetic and immune profiles. The method enables doctors to avoid unnecessary modifications in the treatment regimen while making effective choices of how to treat the condition. Through more research into the same, it is expected that personalized medicine will be applied in the future for the condition.
Digital Biomarkers, Telehealth and Remote Monitoring Expand MS Management
The development of digital healthcare solutions is enhancing MS management through connectivity and convenience. Telemedicine enables the patient to speak to the neurologist without visiting hospitals too often. Mobile applications enable the patient to monitor their symptoms, medications, and activities on a daily basis. Remote monitoring solutions also help healthcare professionals observe the progress of the disease between medical appointments. Digital solutions facilitate communication between the patient and the healthcare team as well. They help achieve timely changes in the treatment and promote adherence to the treatment plan.
Disease-Modifying MS Therapies vs Symptom Management: Scope, Goals & Examples
| Factors | Disease-Modifying Therapies | Symptom Management Treatments |
| Purpose | Stop disease progression and minimize relapses | Ease symptoms and increase quality of daily living |
| Focus | Treatment of the disease itself | Treatment of the symptoms like pain, fatigue, and stiffness of muscles |
| Treatment Examples | Immune suppressors and modifiers | Biological medicines, physical therapy |
| Duration of the Therapy | Consistent treatment | As required or along with DMTs |
| Primary Advantage | Aids in decreasing disease activity | Increases quality of life and improves function |
Source: Polaris Market Research Analysis
AI in Multiple Sclerosis: MRI Analysis, Digital Biomarkers & Remote Monitoring
- Artificial intelligence aids the early diagnosis of multiple sclerosis through analysis of brain scans for signs of lesions.
- Machine learning is helpful to neurologists because it increases the accuracy of diagnosis and the speed at which results can be analyzed.
- With artificial intelligence, individual treatment plans can be developed as it analyzes the patient's condition.
- Remote monitoring using artificial intelligence allows monitoring of symptoms and disease activity outside clinical settings.
Source: Polaris Market Research Analysis
Multiple Sclerosis Market Segmentation by DMT Class, Route, Disease Phenotype & Region
The multiple sclerosis market is primarily segmented based on drug type, route of administration, and region.
| By Drug type | By Route of Administration | By Region |
|
|
|
Source: Polaris Market Research Analysis
Multiple Sclerosis Market by Disease-Modifying Therapy Class
The Immunomodulators Segment Accounted for the Largest Revenue Share in 2025
In 2025, the immunomodulators segment held the largest revenue share due to its ability to treat recurrent forms of MS by reducing the progression of symptoms, this treatment primarily minimizes the number of immune cells, modifies their functionality, or inhibits their entry into the central nervous system. The increased demand for immunomodulators stems from their renowned efficacy combined with a relatively safe profile, resulting in a 30% reduction in relapses on average.
On the other hand, the immunosuppressants segment is expected to witness the highest growth throughout the forecast period. The increased use of immunosuppressive medications over the last three decades has aided in the evolution of multiple sclerosis treatment strategies. The prevalent approach is based on the view that multiple sclerosis is primarily a T-cell-mediated autoimmune disorder, which has led to the use of combination therapy to increase drug efficacy. These key factors are fueling demand for multiple sclerosis medications, which is driving the growth of the market.
Multiple Sclerosis Market by Route: Oral, Subcutaneous/Intramuscular Injection & IV Infusion
The Injectable Agents Segment Accounted for the Highest Market Share During the Forecast Period
The injectable agents segment held the highest multiple sclerosis market share during the forecast period. Injectable medications serve a crucial role in changing the course of Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) in people with active disease. Furthermore, the ease of administering these drugs at home contributes significantly to the high demand for injectable medications, driving the growth of the market.
On the other hand, the oral segment is anticipated to experience the fastest growth throughout the forecast period. Due to an increase in demand among people with multiple sclerosis, there has been a significant increase in interest in treatments. Because of its gradual and consistent distribution throughout the body, monomethyl fumarate (Bafiertam) is expected to have few side effects. Ponesimod (Ponvory), which was approved by the FDA in 2021, has been shown in recent studies to reduce brain lesions in comparison to previous trials.
Multiple Sclerosis Treatment Goals: Relapse Control, Disability Slowing & Symptom Management
| Use Case | How It Helps |
| Reducing Relapse Frequency | Lessens the number of times the condition flares up. |
| Slowing Disease Progression | Benefits include delayed disability and maintaining neurological function. |
| Management of Muscle Weakness and Fatigue | Increases strength, energy and mobility of a person. |
| Treatment of Mobility Issues | Supports mobility through multiple sclerosis medication and rehabilitation. |
| Long-Term Neurological Care | Ensures regular monitoring and treatment modifications. |
| Improvement of Quality of Life | Allows people to remain independent and carry out their tasks comfortably. |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Multiple Sclerosis Market Regional Analysis: North America, Europe, Asia Pacific, Latin America & MEA
North America Led the Multiple Sclerosis Market with 45.6% Share in 2025
In 2025, North America multiple sclerosis market accounted for the largest market share in the multiple sclerosis market, owing to an increase in drug approvals, a higher incidence of this disease, and growing governmental efforts in regional countries. The FDA's implementation of the Generic Drug User Fee Amendments (GDUFA) is an example of this. This amendment aims to reduce business costs while increasing public access to dependable and effective generic pharmaceuticals. Multiple sclerosis affects approximately 2.8 million people worldwide and approximately a million people in the United States, according to the National Multiple Sclerosis Society.
Asia Pacific Multiple Sclerosis Market to Grow Fastest at 8.9% CAGR
Asia Pacific multiple sclerosis market accounted for the fastest growth. The growth can be attributed to increased government initiatives, lower treatment costs, and an increase in available treatment options. For instance, the establishment of the China National Registry of Central Nervous System Inflammatory Demyelinating Illnesses in 2021 aimed to provide a comprehensive overview of multiple sclerosis (MS) and related conditions, thereby facilitating comprehensive disease management.
Source: Polaris Market Research Analysis
Multiple Sclerosis Market Competitive Landscape & Leading Companies
The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge.
Leading Multiple Sclerosis Drug Companies by Marketed Portfolio & Pipeline
- Hoffmann-La Roche Ltd.
- Bayer Healthcare AG
- Teva Pharmaceuticals
- GlaxoSmithKline
- AbbVie Inc.
- Sonafi Pasteur
- Pfizer Inc.
- Merck & Company
- Novartis AG
- AB Science
- Opexa
Multiple Sclerosis Market Future Outlook: BTK Inhibitors, Remyelination & Personalized Care
The market for multiple sclerosis will continue to expand steadily as the demand for newer treatments is increasing. Companies are developing the next generation of disease-modifying drugs and immune therapies. The development of personalized medicines and biomarkers helps to enhance the selection process and patient outcomes. Digital technologies are playing a vital role in improving patient monitoring and management. New advances in diagnostic techniques may lead to early diagnosis and quick treatment. Innovations in the field of neuroprotective and remyelination therapy are creating new opportunities. Higher investment in healthcare is likely to aid in future market growth.
Recent Multiple Sclerosis Drug Approvals, Pipeline Updates & Generic Launches, 2025-2026
- June 2026: Sanofi revealed that the European Commission approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses. The company stated that the approval is based on results from the HERCULES phase 3 study and supporting data from the GEMINI 1 and GEMINI 2 phase 3 studies.(source: sanofi.com)
- January 2026: ScinoPharm Taiwan announced securing U.S. FDA approval for Glatiramer Acetate Injection, a treatment for MS. The company stated that the achievement underscores its leadership in complex generics. It highlights the growing recognition of Taiwan as a trusted contributor to the global pharma sector.(source: scinopharm.com)
We strive to offer our clients the finest in market research with the most reliable and accurate research findings. We use industry-standard methodologies to offer a comprehensive and authentic analysis of the multiple sclerosis market. Besides, we have stringent data-quality checks in place to enable data-driven decision-making for you.
Multiple Sclerosis Market Scope, Segmentation & Forecast Period
| Report Attributes | Details |
| Market size value in 2025 | USD 27.59 billion |
| Market size value in 2026 | USD 28.95 billion |
| Revenue forecast in 2034 | USD 43.91 billion |
| CAGR | 5.30% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments Covered | By Drug Type, By Route of Administration, By Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Customization | Report customization as per your requirements with respect to countries, region, and segmentation |
Source: Polaris Market Research Analysis
We strive to offer our clients the finest in market research with the most reliable and accurate research findings. We use industry-standard methodologies to offer a comprehensive and authentic analysis of the Multiple Sclerosis Market. Besides, we have stringent data-quality checks in place to enable data-driven decision-making for you.
Browse Our More Top Selling Reports:
Over-The-Top Devices And Services Market Size & Share
Automotive Electronics Market Size & Share
Eye Tracking Market Size & Share
Multiple Sclerosis Market FAQ's
The global multiple sclerosis market size is projected to reach USD 43.91 billion by 2034.
Some of the key players in the market are Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, and GlaxoSmithKline.
North America contributes notably to the global multiple sclerosis market growth.
The global multiple sclerosis market is expected to grow at a CAGR of 5.30% during the forecast period.
The multiple sclerosis market report covering key segments are drug type, route of administration, and region.
Multiple sclerosis is a condition where the body’s immune system starts attacking the protective shield of the nerves found in the spinal cord and the brain. The exact cause of this condition remains unknown, but genetic and environmental factors are thought to be involved.
Disease-modifying agents help decrease the number of relapses, delay the progression of the disease, and minimize nerve damage. Disease-modifying agents have an important place in the management of the disease.
Growing awareness about the disease, increased diagnoses, improvement in disease-modifying agents, advancement in personalized medicines, and investments in neurology are some of the factors that are contributing to the growth of the multiple sclerosis market.
Download Sample Report of Multiple Sclerosis Market
Please fill out the form to request a customized copy of the research report.
